2025-05-27 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the provided data.  The report is structured as requested, starting with key numbers and moving to a more detailed analysis.

## TG Therapeutics Inc. (TGTX) Analysis

**Ticker:** TGTX
**Company Description:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 65.97%
*   **VOO Cumulative Return:** 79.45%
*   **Absolute Divergence:** -13.5
*   **Divergence Range:** Max: 395.2, Min: -115.8
*   **Relative Divergence:** 20.0

**Analysis:**

TGTX has underperformed the S&P 500 (VOO) with a cumulative return difference of -13.5%. The relative divergence of 20.0 suggests that TGTX's performance is positioned in the lower range of its historical performance relative to the S&P 500. The wide divergence range (395.2 to -115.8) indicates substantial volatility in TGTX's relative performance.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta  | Cap(B) |
| :--------- | :------ | :---- | :----- | :---- | :----- |
| 2015-2017  | -6.0%   | 56.5% | -35.0% | -0.1  | 1.3    |
| 2016-2018  | -8.0%   | 58.6% | -26.0% | -0.0  | 0.7    |
| 2017-2019  | 74.0%   | 58.6% | 44.0%  | -0.0  | 1.8    |
| 2018-2020  | 402.0%  | 58.6% | 377.0% | -0.1  | 8.3    |
| 2019-2021  | 125.0%  | 63.5% | 70.0%  | -0.2  | 3.0    |
| 2020-2022  | -76.0%  | 70.4% | -82.0% | -0.3  | 1.9    |
| 2021-2023  | -350.0% | 70.4% | -367.0%| -0.8  | 2.7    |
| 2022-2024  | 71.0%   | 73.1% | 54.0%  | -1.0  | 4.8    |
| 2023-2025  | 73.0%   | 84.7% | 46.0%  | 0.3   | 5.5    |

**Analysis:**

*   **CAGR:** Highly variable, ranging from -350% to 402%, indicating inconsistent growth.
*   **MDD:** Consistently high Maximum Drawdown, showing significant downside risk.
*   **Alpha:** Alpha fluctuates significantly, suggesting periods of both outperformance and underperformance relative to the market.
*   **Beta:** The beta is mostly negative or close to zero, indicating that TGTX's price movements are not highly correlated with the market.
*   **Cap(B):** Market capitalization varies, peaking in 2018-2020, which correlates with the highest CAGR and Alpha.

### 2. Recent Price Action

*   **Current Price:** 34.57
*   **Previous Close:** 34.24
*   **Change:** 0.96%
*   **5-Day Moving Average:** 34.69
*   **20-Day Moving Average:** 36.91
*   **60-Day Moving Average:** 37.98

**Analysis:**

The current price is below both the 20-day and 60-day moving averages, which could be interpreted as a bearish signal. However, the price is slightly below the 5-day moving average. The 0.96% price increase since the last close indicates some recent positive momentum.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 35.53 (Approaching Oversold)
*   **PPO:** -0.37
*   **Hybrid Signal:** cash_80%_Sell (80% of holdings)
*   **Recent Relative Divergence Change (20-day):** 0.9 (+) (Short-term Increase)
*   **Expected Return:** -195.3%

**Analysis:**

*   **MRI:** Suggests low risk according to the defined ranges.
*   **RSI:**  Approaching oversold territory, suggesting potential for a price rebound.
*   **PPO:** Negative PPO suggests the stock is currently in a downtrend.
*   **Hybrid Signal:** Recommends selling 80% of holdings, indicating a cautious outlook.
*   **Recent Relative Divergence Change:** The recent increase in relative divergence suggests some short-term positive momentum compared to the S&P 500.
*   **Expected Return:** The highly negative expected return (-195.3%) indicates a very pessimistic outlook for long-term investment compared to the S&P 500.

### 4. Recent News & Significant Events

*   **[2025-05-27]** Major business developments, regulatory changes, or market events.
*   **[2025-05-26]** Analysts discussing recent performance and outlook in the context of industry trends and global economic factors.
*   **[2025-05-25]** Notable volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-05-23]** Market experts highlight risks and opportunities, advising monitoring of news and company announcements.

**Analysis:**

The recent news suggests that TGTX is experiencing significant events that are influencing its stock price. Volatility is noted, and analysts are actively discussing the company's outlook. Monitoring company announcements and news is crucial.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
| :--------- | :---- | :--------- |
| 2025-05-09 | 0.03  | 0.12 B$  |
| 2024-11-07 | 0.03  | 0.08 B$  |
| 2024-08-09 | 0.05  | 0.07 B$  |
| 2024-05-06 | -0.07 | 0.06 B$  |
| 2025-05-09 | -0.07 | 0.06 B$  |

**Analysis:**

*   Recent earnings show mixed results. The most recent EPS is positive (0.03), but previous quarters had negative EPS.
*   Revenue has generally been increasing, from 0.06B$ to 0.12B$ over the observed period.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-03-31 | $0.12B | 87.14%        |
| 2024-12-31 | $0.11B | 85.77%        |
| 2024-09-30 | $0.08B | 88.86%        |
| 2024-06-30 | $0.07B | 88.70%        |
| 2024-03-31 | $0.06B | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
| :--------- | :------ | :------- |
| 2025-03-31 | $0.24B | 2.13%    |
| 2024-12-31 | $0.22B | 10.49%   |
| 2024-09-30 | $0.19B | 2.02%    |
| 2024-06-30 | $0.18B | 3.87%    |
| 2024-03-31 | $0.16B | -6.69%   |

**Analysis:**

*   **Revenue:** Shows a consistent upward trend over the past year, which is a positive sign.
*   **Profit Margin:** Consistently high, indicating good cost control and efficient operations.
*   **Equity:** Increasing, which shows the company is building its asset base.
*   **ROE:** Fluctuates significantly. The ROE needs to be consistently positive and growing for a healthy financial outlook.

### 7. Overall Analysis

TG Therapeutics Inc. (TGTX) presents a mixed picture.

*   **Positives:**  Increasing revenue, high profit margins, recent positive EPS, approaching oversold RSI, recent short-term positive momentum, and low MRI.
*   **Negatives:** Underperformance relative to the S&P 500, high volatility, negative expected return, recommendations to sell holdings, price below key moving averages, fluctuating ROE, news pointing to volatility and uncertainty.

**Conclusion:**

Based on the data, TGTX appears to be a high-risk investment. While recent earnings are positive and revenue is growing, the significant underperformance compared to the S&P 500, high volatility, and negative long-term expected return raise concerns. The recommendation to sell 80% of holdings further reinforces a cautious stance. Investors should closely monitor company news and announcements, particularly regarding business developments, regulatory changes, and market events, to make informed decisions. The recent short-term positive momentum should be viewed with caution in light of the overall negative outlook.
